Diabetes News

Compared with boys, girls with type 1 diabetes have worse HbA1c, higher BMI and more diabetic ketoacidosis and require higher insulin doses, according to a systematic review published in Diabetologia.

The Kidney Disease Improving Global Outcomes updated the clinical practice guidelines for treating patients with diabetes and chronic kidney disease to recommend new practices, according to a press release.

In patients with chronic pancreatitis, disease characteristics and individual risk factors could help clinicians prevent the development of type 2 diabetes, according to a press release from Cedars-Sinai Medical Center.

Adults with type 2 diabetes who use a GLP-1 receptor agonist for more than 1 year may have an increased risk for thyroid cancer, according to findings published in Diabetes Care.

Applying optimal defaults to online grocery shopping resulted in the promotion of healthier grocery purchases among adults with or at risk for type 2 diabetes, researchers reported in Obesity.

In this video, Paula LeClair, MBA, MHCDS, U.S. general manager at Healthy.io and chairperson for the American Diabetes Association Board in New England, discusses how the Minuteful Kidney test can improve screening adherence for chronic kidney disease.

The FDA has approved teplizumab to delay the onset of type 1 diabetes for both adults and children aged 8 years and older with stage 2 type 1 diabetes, according to an agency press release.

The FDA has approved teplizumab to delay the onset of type 1 diabetes for both adults and children aged 8 years and older with stage 2 type 1 diabetes, according to an agency press release.

ORLANDO — Isuzinaxib, a pan-NOX inhibitor modulating oxidative stress by Aptabio significantly reduced urine albumin-to-creatinine ratio in patients with type 2 diabetes and chronic kidney disease, according to data at ASN Kidney Week.

CHICAGO — A meta-analysis of 13 large SGLT2 inhibitor trials, including the recently published EMPA-KIDNEY trial, indicates that the drug class reduces CV and renal outcomes across all high-risk groups, with and without type 2 diabetes.